Composite end points in randomized trials: there is no free lunch

JAMA. 2010 Jan 20;303(3):267-8. doi: 10.1001/jama.2009.2017.

Authors

George Tomlinson¹, Allan S Detsky

Affiliation

¹ Department of Health Policy Management and Evaluation, University of Toronto, Ontario, Canada.

PMID: 20085955
DOI: 10.1001/jama.2009.2017

No abstract available

MeSH terms

Decision Making
Diabetes Mellitus / mortality
Diabetes Mellitus / prevention & control
Endpoint Determination*
Humans
Hypoglycemic Agents / therapeutic use
Randomized Controlled Trials as Topic*
Rosiglitazone
Thiazolidinediones / therapeutic use
Treatment Outcome*

Substances

Hypoglycemic Agents
Thiazolidinediones
Rosiglitazone